SB 399-FN - AS AMENDED BY THE SENATE
02/08/2024 0405s
2024 SESSION
24-2946
05/08
SENATE BILL 399-FN
AN ACT relative to insurance coverage for blood testing associated with elevated lead levels.
SPONSORS: Sen. Birdsell, Dist 19; Sen. Avard, Dist 12; Sen. Ricciardi, Dist 9; Sen. Rosenwald, Dist 13; Sen. Innis, Dist 7; Sen. Soucy, Dist 18; Sen. Whitley, Dist 15; Sen. Chandley, Dist 11; Sen. Bradley, Dist 3; Rep. Thackston, Ches. 12; Rep. J. Sullivan, Graf. 2; Rep. Burroughs, Carr. 2; Rep. Potucek, Rock. 13
COMMITTEE: Health and Human Services
─────────────────────────────────────────────────────────────────
AMENDED ANALYSIS
This bill provides that health insurance coverage for blood lead testing shall not be subject to a co-payment, deductible, or coinsurance. The bill also requires coverage for follow-up blood testing that is necessary to complete the preventive screening when the initial blood testing indicates an elevated blood lead level or is inconclusive.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Explanation: Matter added to current law appears in bold italics.
Matter removed from current law appears [in brackets and struckthrough.]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
02/08/2024 0405s 24-2946
05/08
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Twenty Four
AN ACT relative to insurance coverage for blood testing associated with elevated lead levels.
Be it Enacted by the Senate and House of Representatives in General Court convened:
1 Short Title. This act shall be known as the lead poisoning prevention and treatment act of 2024.
2 Accident and Health Insurance. Amend RSA 415:6-v to read as follows:
415:6-v Coverage for Blood Lead Testing. Each insurer that issues or renews any individual policy, plan, or contract of accident or health insurance providing benefits for medical or hospital expenses shall provide to persons covered by such insurance who are residents of this state coverage for the costs of blood lead testing conducted pursuant to RSA 130-A:5-a. Benefits provided under this section shall not be subject to any [greater] co-payment, deductible, or coinsurance [than any other similar benefits provided by the insurer]. Benefits provided under this section shall include any follow-up blood lead testing that is necessary to complete the preventive screening when the initial blood lead testing indicates an elevated blood lead level or is inconclusive.
3 Accident and Health Insurance. Amend RSA 415:18-aa to read as follows:
415:18-aa Coverage for Blood Lead Testing. Each insurer that issues or renews any policy of group or blanket accident or health insurance providing benefits for medical or hospital expenses shall provide to each group, or to the portion of each group comprised of certificate holders of such insurance who are residents of this state, coverage for the costs of blood lead testing conducted pursuant to RSA 130-A:5-a. Benefits provided under this section shall not be subject to any [greater] co-payment, deductible, or coinsurance [than any other similar benefits provided by the insurer]. Benefits provided under this section shall include any follow-up blood lead testing that is necessary to complete the preventive screening when the initial blood lead testing indicates an elevated blood lead level or is inconclusive.
4 Effective Date. This act shall take effect 60 days after its passage.
24-2946
Amended 2/21/24
SB 399-FN- FISCAL NOTE
AS AMENDED BY THE SENATE (AMENDMENT #2024-0405s)
AN ACT relative to insurance coverage for blood testing associated with elevated lead levels.
FISCAL IMPACT: [ ] State [ ] County [ ] Local [ X ] None
METHODOLOGY:
The Office of Legislative Budget Assistant states this bill, as amended by the Senate, has no fiscal impact on state, county and local expenditures or revenue.
AGENCIES CONTACTED:
Insurance Department
| Date | Amendment |
|---|---|
| Feb. 1, 2024 | 2024-0405s |
| Date | Body | Type |
|---|---|---|
| Jan. 3, 2024 | Senate | Hearing |
| Feb. 8, 2024 | Senate | Floor Vote |
| April 23, 2024 | House | Hearing |
April 9, 2024: Public Hearing: 04/23/2024 01:45 pm LOB 302-304
Feb. 29, 2024: Introduced (in recess of) 02/22/2024 and referred to Commerce and Consumer Affairs HJ 6
Feb. 8, 2024: Ought to Pass with Amendment 2024-0405s, MA, VV; OT3rdg; 02/08/2024; SJ 3
Feb. 8, 2024: Committee Amendment # 2024-0405s, AA, VV; 02/08/2024; SJ 3
Feb. 1, 2024: Committee Report: Ought to Pass with Amendment # 2024-0405s, 02/08/2024; Vote 5-0; CC; SC 6
Dec. 15, 2023: Hearing: 01/03/2024, Room 101, LOB, 01:45 pm; SC 49
Dec. 12, 2023: To Be Introduced 01/03/2024 and Referred to Health and Human Services; SJ 1